Тёмный

Minds & Molecules: Lessons from Alzheimer's Research 

Drug Hunter
Подписаться 2,1 тыс.
Просмотров 981
50% 1

Despite limited success with amyloid-targeting biologics, Alzheimer's disease (AD) remains a neurodegenerative disorder in dire need of new directions and new thinking to augment ongoing approaches. Instead of seeking a single "magic bullet" for AD, a multifaceted approach is more likely to lead to success. Targets involved in neuroinflammation have emerged for the treatment of AD.
00:23 Introduction
03:38 Ice-breaker questions
16:14 Presentation
48:21 Q&A
Presented by Donald Weaver Professor of Chemistry, Pharmaceutical Sciences and Medicine at the University of Toronto with host Dennis Koester, Director of Industry Research and Relations, Drug Hunter
Presented on June 13, 2024, as a Drug Hunter Flash Talk.
Sign up for future sessions here: drughunter.com...

Опубликовано:

 

28 сен 2024

Поделиться:

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист
Посмотреть позже
Комментарии : 8   
@invictusfate7195
@invictusfate7195 3 месяца назад
Thank you for the nice presentation. Does this mean that current ABeta targeting therapeutics such as donanemab could lead to increased infections in patients under treatment?
@loveKG26
@loveKG26 3 месяца назад
Wow not good since infections and inflammation can cause amyloid….. leave the infection or inflammation not targeted and get a patient with memory and cognitive issues…. Time to play drug deals…..
@Truth_Seeker567
@Truth_Seeker567 3 месяца назад
Thank you so much Dennis for bringing these great people to share their knowledge.
Далее
Reduce dementia risk
50:27
Просмотров 611 тыс.
Supplements For Resolving Neuro-inflammation
17:59
Просмотров 61 тыс.